Investigational drugs for assisting psychotherapy for posttraumatic stress disorder (PTSD): emerging approaches and shifting paradigms in the era of psychedelic medicine

Click to increase image sizeClick to decrease image size

Acknowledgments

LAA’s salary was partially supported by IK2CX001873 of the U.S. Department of Veterans Affairs, Office of Research & Development, Clinical Science Research & Development Service, the American Foundation for Suicide Prevention (YIA-0-04-116), and the Brain and Behavior Foundation. CGA’s salary was partially supported by Beth K. Stuart Yudofsky Chair in the Neuropsychiatry of Military Post Traumatic Stress Syndrome.

Declaration of interest

LAA has served as a consultant, speaker, and/or on advisory boards for Guidepoint, Usona Institute, Research for Hope, and Transcend Therapeutics. CGA has served as a consultant, speaker, and/or on advisory boards for Genentech, Janssen, Psilocybin Labs, Lundbeck, Guidepoint and FSV7, and editor of Chronic Stress for Sage Publications, Inc. He also filed a patent for using mTORC1 inhibitors to augment the effects of antidepressants (August 20, 2018).

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers in this manuscript have no relevant financial or other relationships to disclose

Additional information

Funding

This paper was not funded